ARTICLE IN PRESS

Biochimica et Biophysica Acta xxx (2015) xxx-xxx



Contents lists available at ScienceDirect

Biochimica et Biophysica Acta



BBADIS-64175; No. of pages: 12; 4C: 2, 3, 4, 6, 8

journal homepage: www.elsevier.com/locate/bbadis

1 Review

QI Sirtuins in vascular diseases: Emerging roles and therapeutic potential

Q2 Nunzia D'Onofrio¹, Milena Vitiello¹, Rosario Casale, Luigi Servillo, Alfonso Giovane, Maria Luisa Balestrieri^{*}

4 Department of Biochemistry, Biophysics and General Pathology, School of Medicine and Surgery, Second University of Naples, via L. De Crecchio 7, 80138 Naples, Italy

5 ARTICLE INFO

Article history 6 Received 18 December 2014 Received in revised form 20 February 2015 Accepted 4 March 2015 Available online xxxx 10 Keywords: 11 12Sirtuins 13 Endothelium 14 Vascular dysfunction Endothelial progenitor cell 1516 Cardiovascular disease

ABSTRACT

Silent information regulator-2 (Sir-2) proteins, or sirtuins, are a highly conserved protein family of histone 17 deacetylases that promote longevity by mediating many of the beneficial effects of calorie restriction which ex- 18 tends life span and reduces the incidence of cancer, cardiovascular disease (CVD), and diabetes. Here, we review 19 the role of sirtuins (SIRT1-7) in vascular homeostasis and diseases by providing an update on the latest knowl- 20 edge about their roles in endothelial damage and vascular repair mechanisms. Among all sirtuins, in the light 21 of the numerous functions reported on SIRT1 in the vascular system, herein we discuss its roles not only in the 22 control of endothelial cells (EC) functionality but also in other cell types beyond EC, including endothelial progen- 23 itor cells (EPC), smooth muscle cells (SMC), and immune cells. Furthermore, we also provide an update on the 24 growing field of compounds under clinical evaluation for the modulation of SIRT1 which, at the state of the art, 25 represents the most promising target for the development of novel drugs against CVD, especially when concom- 26 itant with type 2 diabetes. 27

© 2015 Published by Elsevier B.V.

33 1. Introduction

28 **39** 31

03

The structural and functional changes of the vasculature are strictly linked to vascular aging processes and other risk factors for

Abbreviations: ACE, angiotensin converting enzyme; AICAR, 5-amino-4-imidazolecarboxamide riboside; AMPK, AMP-activated protein kinase; Ang II, angiotensin II; ApoE, apolipoprotein E: AT1R, angiotensin II type 1 receptor: ATM, ataxia telangiectasia mutated: ATP, adenosine triphosphate; CaMKK β , Ca2 +/calmodulin-dependent protein kinase β ; COPD, chronic obstructive pulmonary disease; CSE, cigarette smoke extract; CVD, cardiovascular disease; DDAH2, dimethylarginine dimethylaminohydrolase; DDR, DNA damage response; EC, endothelial cells; ELAV, embryonic lethal abnormal vision; eNOs, endothelial nitric oxide; EPC, endothelial progenitor cells; FGFR 21, fibroblast growth factor 21; FOXO, forkheadbox O transcription factor; GHD, glutamate dehydrogenase; HIF, hypoxiainducible factor; HUVEC, human umbilical vein endothelial cells; ICAM-1, intercellular adhesion molecule-1; IGC, intensive glycemic control; IL, interleukin; KDR, kinase-domain insert containing receptor; LDL, low density lipoprotein; LKB1, serine/threonine kinase B1; MCP-1, monocyte chemoattractant protein-1; MnSOD, manganese superoxide dismutase; NAD+, nicotinamide adenine dinucleotide; NAM, nicotinamide; NAMPT, nicotinamide phosphoribosyltransferase; NBS1, repair protein Nijmegen Breakage Syndrome-1; NF-KB, Nuclear factor-kappaB; NO, nitric oxide; PAI, plasminogen activator inhibitor; PCI, percutaneous coronary intervention; PDH, pyruvate dehydrogenase complex; PGC-1α, peroxisome proliferator-activated receptor gamma coactivator 1-alpha; PPAR-α, peroxisome proliferator-activated receptor alfa; RFX5, regulatory factor for X-box; ROS, reactive oxygen species; Sir2, silent information regulator 2; SIRT, sirtuin; SIN-1, 3-morpholinosydnonimine; SMC, smooth muscle cells; SNP, single nucleotide polymorphisms; STEMI, ST-segment elevation myocardial infarction; TIMP3, tissue inhibitor of metalloproteinase 3; TNF- α , tumor necrosis factor- α ; UCP, uncoupling protein; VCAM-1, vascular cell adhesion molecule-1: VEGF, vascular endothelial growth factor

* Corresponding author at: Department of Biochemistry, Biophysics and General Pathology, Second University of Naples, via L. De Crecchio 7, 80138 Naples, Italy. Tel.: +39 081 5667635; fax: +39 081 5665863.

E-mail address: marialuisa.balestrieri@unina2.it (M.L. Balestrieri).

¹ Equally contributed to this work.

http://dx.doi.org/10.1016/j.bbadis.2015.03.001 0925-4439/© 2015 Published by Elsevier B.V. cardiovascular diseases (CVD), such as hypercholesterolemia, hyperten- 36 sion, smoking, and diabetes. Specifically, the complex phenomenon of 37 vascular dysfunction involves aging-related deterioration of the vascu- 38 lature and secondary stresses, such as metabolic disorders, altered nitric 39 oxide (NO) pathway, and increased inflammation and oxidative stress 40 [1–5]. Particularly, the reduction of NO bioavailability caused by its di- 41 minished synthesis and/or by its augmented scavenging due to oxida- 42 tive stress, along with the increased platelet aggregation, cytokines 43 production, and adhesion molecule and chemokine expression, are the 44 main intracellular events leading to endothelial dysfunction and vascu- 45 lar damage [1–5]. 46

The epigenetic changes of histone and non-histone protein 47 deacetylation catalyzed by sirtuins, or silent information regulator 48 2 (Sir2) proteins, take part to the mechanisms regulating vascular 49 dysfunction related to aging, CVD and, most of all, vascular complica- 50 tions during diabetes [1,6–9]. Beyond controversy about the influence 51 of Sir2 on lifespan extension in *C. elegans* and *Drosophila melanogaster* **Q4** [10–12], the first evidence showing the connection between sirtuins 53 and aging is the observations that overexpression of the sirtuin member 54 Sir2 was able to extend lifespan in yeast, *C. elegans*, and in 55 *D. melanogaster* [13]. Sirtuins, firstly described as modulators of energy 56 metabolism, DNA repair, and oxidative stress responses [13] are 57 known to exert protective effects against age-related diseases such as 58 CVD, cancer, diabetes, and neurodegenerative diseases [13–15].

Mammals hold seven members of the sirtuin family, from SIRT1, the 60 most extensively characterized for its role in aging, to SIRT7, all 61 possessing a common highly conserved catalytic domain and nicotin- 62 amide adenine dinucleotide (NAD⁺)-binding site. They have different 63 subcellular localization, tissue specificity, activity, and targets [16]. 64

Please cite this article as: N. D'Onofrio, et al., Sirtuins in vascular diseases: Emerging roles and therapeutic potential, Biochim. Biophys. Acta (2015), http://dx.doi.org/10.1016/j.bbadis.2015.03.001

2

ARTICLE IN PRESS

SIRT1 is localized both in the nucleus and cytosol and the signal from 65 66 nucleus to cytosol occurs following specific conditions [17]. SIRT2 is cytosolic but also nuclear in certain phase of the cell cycle [18]. SIRT3, 67 68 SIRT4 and SIRT5 are mitochondrial [19], while SIRT6 and SIRT7 are nu-69 clear and nucleolar, respectively [20,21]. As for the catalytic activities, 70SIRT1, SIRT2, SIRT3, SIRT5 SIRT6 and SIRT7 act as deacetylase enzymes 71using NAD⁺ to cleave acetyl groups from ε -acetyl lysine residues of 72target proteins in a reaction that generates nicotinamide (NAM), 2'-O-73acetyl-ADP-ribose, and deacetylated substrates [22] (Fig. 1).

74SIRT4, as well as SIRT6, acts as a mono-ADP-ribosyltransferase, in a reaction where the ADP-ribosyl moiety of NAD⁺ is transferred to a 75substrate protein [19,23]. It has been demonstrated that SIRT4 acts as 76 lipoamidase that regulates the pyruvate dehydrogenase complex 77(PDH) and, importantly, its catalytic efficiency for lipoyl- and biotinyl-78 lysine modifications is superior to its deacetylation activity [24]. As for 79 80 SIRT6, this deacetylase can locate at the endoplasmic reticulum and controls protein lysine fatty acylation [25]. Indeed, as revealed by crystal 81 82 structure, SIRT6 possesses a large hydrophobic pocket able to accommodate long chain fatty acyl groups and efficiently remove them from 83 lysine residues [25]. Beside the deacetylase activity, SIRT5 also shows 84 demalonylase and desuccinylase activity [26] (Fig. 1). 85

Sirtuin chromatin-associated functions are also exerted through the
modulation of epigenetic information by direct deacetylation of specific
histone acetylation marks [27]. Among mammalian sirtuins, SIRT1
and SIRT6 are the most functionally important deacetylase of histone

(H) 3 acetylated (Ac) on lysine (K) 9 (H3K9Ac). SIRT1 deacetylation of 90 H3K9Ac and H4K16Ac is directly associated with its capacity to coordi-91 nate the formation of constitutive and facultative heterochromatin [27]. 92 Other histone substrates of SIRT1 are H1K27Ac, H3K9Ac, H3K14Ac, 93 H3K18Ac, H3K56Ac, H4K12Ac, and 6 H4K6Ac. SIRT6 H3K9Ac 94 deacetylase activity is important for modulating telomere structure 95 and DNA repair of double-strand breaks [27]. 96

Given the array of potentially beneficial effects of sirtuin modulation 97 on cardiovascular health, the interest in developing specific modulators 98 is keeping increasing [28–30]. Indeed, although the role of SIRT1 on 99 longevity *per se* is not fully convincing because transgenic mice over- 100 expressing SIRT1 did not show to live longer than controls, to date, 101 the efficacy of SIRT1 in protecting mice against age-associated diseases 102 unveils an important role in improving health span and preventing 103 CVD [14,31]. At vascular level, given that all seven sirtuins are expressed 104 in vascular endothelial cells (EC), SIRT1 is the only member of the 105 sirtuin family shown to uniquely regulate EC physiology by promoting 106 vasodilatory and regenerative functions of the vascular wall through 107 the modulation of endothelial nitric oxide synthase (eNOS) activity, 108 forkhead box O1 (FOXO1), p53, and angiotensin II (Ang II) type 1 receptor (AT1R) [28,32,33].

Over the recent years, in addition to SIRT1, the function of other 111 sirtuins in vascular physiology has been investigated and some of 112 them are likely to have roles in the normal and diseased blood vessels. 113 Among these, recent advances have been made on the role of SIRT3, a 114



Fig. 1. Enzymatic activities of sirtuins. The seven sirtuins are categorized into four classes, class I (SIRT1, SIRT2, and SIRT3), class II (SIRT4), class III (SIRT5), and class IV (SIRT6 and SIRT7). Mammalian sirtuins have primarily two different NAD⁺-consuming activities. SIRT1, SIRT2, SIRT3, SIRT5 SIRT6 and SIRT7 act as deacetylase enzymes using NAD⁺ to cleave acetyl groups from ε-acetyl lysine residues of target proteins in a reaction that generates NAM and 2'-O-acetyl-ADP-ribose, SIRT4 and SIRT6 act as a mono-ADP-ribosyltransferase, in a reaction where the ADP-ribosyl moiety of NAD⁺ is transferred to a substrate protein. SIRT6 how the nzymatic activities and, also, efficiently removes long chain fatty acyl groups from lysine residues. Moreover, SIRT4 acts as a cellular lipoamidase and SIRT5 acts as demalonylase, by removing malonyl (Mal) or succinyl moiety (Suc) from target proteins. NAD⁺, nicotinamide adenine dinucleotide; NAM, nicotinamide; ADP: adenosine diphosphate.

Please cite this article as: N. D'Onofrio, et al., Sirtuins in vascular diseases: Emerging roles and therapeutic potential, Biochim. Biophys. Acta (2015), http://dx.doi.org/10.1016/j.bbadis.2015.03.001

Download English Version:

https://daneshyari.com/en/article/8259776

Download Persian Version:

https://daneshyari.com/article/8259776

Daneshyari.com